Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Sharma, Akshay  [Clear All Filters]
Journal Article
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, et al. Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022.
Bhatt VRaj, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MMAl, Badawy SM, Beitinjaneh A, Ganguly S, et al. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. Transplant Cell Ther. 2021.
Sharma A, Bhatt NS, St Martin A, Abid MBilal, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales M-A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021.
Bhatt NS, Sharma A, St Martin A, Abid MBilal, Brown VI, Diaz MA, Frangoul H, Gadalla SM, Herr MM, Krem MM, et al. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Haematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplant Cell Ther. 2022.
Sharma A, Boelens J-J, Cancio M, Hankins JS, Bhad P, Azizy M, Lewandowski A, Zhao X, Chitnis S, Peddinti R, et al. CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023;389(9):820-832.
Sharma A, Galimard J-E, Pryce A, Bhoopalan SVelan, Dalissier A, Dalle J-H, Locatelli F, Jubert C, Mirci-Danicar O, Kitra-Roussou V, et al. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study. Bone Marrow Transplant. 2024.
Leonard A, Sharma A, Uchida N, Stroncek D, Panch SR, West K, Molloy E, Hughes TE, Hauffe S, Taylor T, et al. Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Adv. 2021;5(9):2403-2411.
Lucas AGTroullio, Lindemans CA, Bhoopalan SVelan, Dandis R, Prockop SE, Naik S, Keerthi D, de Koning C, Sharma A, Nierkens S, et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023.
Belbachir S, Abraham A, Sharma A, Prockop S, DeZern AE, Bonfim C, Bidgoli A, Li J, Ruggeri A, Bertaina A, et al. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Bos S, Murray J, Marchetti M, Cheng G-S, Bergeron A, Wolff D, Sander C, Sharma A, Badawy SM, Peric Z, et al. ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft--host disease in adults. Eur Respir J. 2024.
Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024.
Métais J-Y, Doerfler PA, Mayuranathan T, Bauer DE, Fowler SC, Hsieh MM, Katta V, Keriwala S, Lazzarotto CR, Luk K, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019;3(21):3379-3392.
Bhoopalan SVelan, Suryaprakash S, Sharma A, Wlodarski MW. Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: state of the art and science. Front Oncol. 2023;13:1236038.
Farhadfar N, Ahn KWoo, Bo-Subait S, Logan B, Stefanski H, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, et al. The impact of pre-apheresis Health Related Quality of Life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplant Cell Ther. 2022.
Sharma A, Logan B, Estrada-Merly N, Lehmann LE, Rangarajan HG, Preussler JM, Troy JD, Akard LP, Bhatt NS, Truong TH, et al. Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers. Transplant Cell Ther. 2023.
Garcia-Rosa M, Abraham A, Bertaina A, Bhoopalan SVelan, Bonfim C, Cohen S, Dezern A, Louis C, Oved J, Pavel-Dinu M, et al. International society for cell & gene therapy stem cell engineering committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 2023.
Woodard KJ, Doerfler PA, Mayberry KD, Sharma A, Levine R, Yen J, Valentine V, Palmer LE, Valentine M, Weiss MJ. Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations. Dis Model Mech. 2022;15(6).
Knight TE, Ahn KWoo, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, et al. No impact of CD34 cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant. 2023.
Mayuranathan T, Newby GA, Feng R, Yao Y, Mayberry KD, Lazzarotto CR, Li Y, Levine RM, Nimmagadda N, Dempsey E, et al. Potent and uniform fetal hemoglobin induction via base editing. Nat Genet. 2023.
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, et al. Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2019.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, et al. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. 2023.
John TD, Maron G, Abraham A, Bertaina A, Bhoopalan SVelan, Bidgoli A, Bonfim C, Coleman Z, Dezern A, Li J, et al. Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy. 2024.
Klein OR, Bonfim C, Abraham A, Ruggeri A, Purtill D, Cohen S, Wynn R, Russell A, Sharma A, Ciccocioppo R, et al. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy. 2023.
Taylor M, Cole SW, Strom J, Brazauskas R, K Baker S, Phelan R, Buchbinder DK, Hamilton BK, Schoemans HM, Shaw BE, et al. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Blood Adv. 2023.